Unilateral transcranial magnetic resonance-guided focused ultrasound Pallidothalamic Tractotomy in X-linked Dystonia-Parkinsonism: A case report
https://doi.org/10.47895/amp.vi0.3727
- Author:
Roland Dominic G. Jamora
1
,
2
;
Wei Lin
3
;
Kevin Wen-Kai Tsai
4
;
Hui-Chin Lai
4
;
Pai-Yi Chiu
5
;
Azalea T. Pajo
1
;
Wei-Chieh Chang
6
;
Takaomi Taira
7
Author Information
1. Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Philippines
2. Movement Disorders Service, Institute for Neurosciences, St. Lukes Medical Center, Global City, Philippines
3. Department of Neurology, Chang Bing Show Chwan Memorial Hospital, Changhua County, Taiwan
4. MR-guided Focused Ultrasound Center, Chang Bing Show Chwan Memorial Hospital, Changhua County, Taiwan
5. Department of Neurology, Show Chwan Memorial Hospital, Changhua City, Taiwan
6. Department of Neurosurgery, Chang Bing Show Chwan Memorial Hospital, Changhua County, Taiwan
7. Department of Neurosurgery, Tokyo Womens Medical University, Tokyo, Japan
- Publication Type:Case Reports
- Keywords:
Focused ultrasound;
Pallidothalamic tractotomy;
Pallidothalamic tract;
XDP;
X-linked dystonia parkinsonism
- MeSH:
Dystonia 3, Torsion, X-Linked;
Dystonic Disorders;
Genetic Diseases, X-Linked
- From:
Acta Medica Philippina
2022;56(17):70-76
- CountryPhilippines
- Language:English
-
Abstract:
X-linked dystonia-parkinsonism (XDP) is an adult-onset debilitating neurodegenerative disorder presenting with
motor and nonmotor symptoms. The treatment options for XDP are limited. We described a patient with XDP who underwent a unilateral transcranial magnetic resonance-guided focused ultrasound (tcMRgFUS) pallidothalamic tractotomy with a one-year follow-up. The patient reported an immediate improvement in his pain after the procedure. Compared to baseline, there was an improvement in his scores in the dystonia (31%), parkinsonism (35.1%), and activities of daily living (71%) subscales at 1-year follow up. The overall improvement at one year was 46%. There were no adverse events noted. Additional studies with larger sample size and follow-up would be needed to document its long-term safety and efficacy.
- Full text:3727-Article Text-80980-1-10-20220928.pdf
